$600 million. That’s the price Alibaba Group and Ant Group’s AUS Merchant Services just paid to make a Justice Department drug-trafficking case disappear.
The non-prosecution agreement, announced July 1, resolves claims that Alibaba.com and AliExpress let merchants sell illegal pharmaceuticals, controlled substances, listed chemicals and pill presses into the U.S., violating the Federal Food, Drug, and Cosmetic Act’s prohibited-acts provision. Alibaba admitted that from January 2016 to December 2024, nearly nine years, it failed to stop roughly 80,000 prohibited transactions worth over $200 million in gross merchandise value, despite having policies on the books that were supposed to restrict exactly that.
AUS’s piece of the failure is narrower but sharper: from 2020 to 2023, its transaction-monitoring system missed payments from high-risk jurisdictions and multiple payors stacked on single invoices, letting its anti-money-laundering program get run around by the same merchants.
The math: Alibaba pays $125 million in penalties plus $200 million forfeited. AUS pays $85 million plus $190 million forfeited. Split penalty-plus-forfeiture structures like this are becoming DOJ’s default tool for marketplace enablement cases, criminal exposure priced into the platform’s compliance budget rather than litigated to a verdict. Both companies now owe the department continued cooperation and enhanced controls, which means audit rights DOJ can invoke again if the next transaction-monitoring gap surfaces.
Nine years is a long time for a “policy on the books” to not translate into enforcement at the transaction layer. Worth auditing your own marketplace’s monitoring thresholds this quarter.
— Rebecca Lauren